FIELD: medicine, pharmaceutics.
SUBSTANCE: group of inventions refers to medicine, namely oncology and can be used for treating tumours. What is offered is application of N-hydroxy-3 [4-[[[2-(2-methyl-1H-indol-3-yl)ethyl]amino]methyl]phenyl]-2E-2-propenamide (compound of formula III) for preparing a drug intended for the use in a combination with ionising radiation. A system under the invention comprises the compound of formula III in a pharmaceutically acceptable form together with a package leaflet, in a combination with ionising radiation.
EFFECT: use of the inventions allows providing higher clinical effectiveness in solid tumours ensured by synergetic action of the compound of formula III and ionising radiation intensified radiation-induced apoptosis and delayed tumour growth.
4 cl, 7 dwg, 1 ex
| Title | Year | Author | Number |
|---|---|---|---|
| COMBINATION OF HDA INHIBITOR AND ANTIMETABOLITE | 2007 |
|
RU2469717C2 |
| APPLICATION OF HDAC INHIBITORS FOR TREATING MYELOMA | 2006 |
|
RU2420279C2 |
| HYDROXAMATE DERIVATIVES SUITABLE AS DEACETYLASE INHIBITORS | 2001 |
|
RU2302408C2 |
| OXOAZEPANYLACETAMIDE AND OXOAZEPANYLPHENOXYACETAMIDE DERIVATIVES, COMPOSITIONS CONTAINING THEM AND METHOD FOR INHIBITING HEPATITIS TYPE C VIRUS (HCV) REPLICATION | 2006 |
|
RU2415132C2 |
| AMINOPIPERIDINE DERIVATIVES AS CETP INACTIVATORS (CHOLESTEROL ESTER TRANSFER PROTEIN) | 2007 |
|
RU2442782C2 |
| USE OF NOX INHIBITORS FOR TREATMENT OF CANCER | 2018 |
|
RU2780354C2 |
| ARYL, HETEROARYL AND HETEROCYCLIC PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF MEDICAL DISORDERS | 2018 |
|
RU2801278C2 |
| PHARMACEUTICAL COMBINATIONS CONTAINING PYRIDO[4,3-d]PYRIMIDINE DERIVATIVES AS HSP90 INHIBITOR AND HER2 INHIBITOR | 2009 |
|
RU2532375C2 |
| HETEROCYCLIC COMPOUNDS FOR TREATING DISEASE | 2016 |
|
RU2727194C2 |
| COMBINATIONS WHICH INCLUDE RECEPTOR S1P AGONIST AND JAK3 KINASE INHIBITOR | 2005 |
|
RU2415678C2 |
